Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$4.22 -0.14 (-3.21%)
Closing price 04:00 PM Eastern
Extended Trading
$4.22 0.00 (-0.12%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. CMRX, CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, and AMLX

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Chimerix (CMRX), Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Chimerix. MarketBeat recorded 3 mentions for 4D Molecular Therapeutics and 0 mentions for Chimerix. 4D Molecular Therapeutics' average media sentiment score of 0.49 beat Chimerix's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
4D Molecular Therapeutics Neutral
Chimerix Neutral

Chimerix has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. 4D Molecular Therapeutics' return on equity of -33.26% beat Chimerix's return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-767,126.06% -33.26% -30.68%
Chimerix N/A -50.78%-44.94%

Chimerix has higher revenue and earnings than 4D Molecular Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$40K4,887.82-$160.87M-$3.18-1.33
Chimerix$212K3,778.71-$82.10M-$0.99-8.63

4D Molecular Therapeutics has a beta of 2.81, indicating that its share price is 181% more volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500.

4D Molecular Therapeutics currently has a consensus price target of $29.56, indicating a potential upside of 600.37%. Chimerix has a consensus price target of $8.53, indicating a potential downside of 0.08%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Chimerix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Chimerix
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

4D Molecular Therapeutics beats Chimerix on 11 of the 16 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$201.98M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-1.334.4521.0120.09
Price / Sales4,887.82709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book0.385.008.125.65
Net Income-$160.87M$30.99M$3.25B$257.91M
7 Day Performance-1.40%1.69%0.97%2.09%
1 Month Performance3.18%9.20%7.36%11.13%
1 Year Performance-72.13%-1.25%31.31%18.40%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.2164 of 5 stars
$4.22
-3.2%
$29.56
+600.4%
-76.0%$201.98M$40K-1.33120
CMRX
Chimerix
0.5692 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CRON
Cronos Group
2.0851 of 5 stars
$2.07
-1.0%
N/A-16.3%$798.36M$117.61M15.92450
QURE
uniQure
2.5964 of 5 stars
$14.55
+1.0%
$37.82
+159.9%
+79.5%$797.05M$27.12M-3.31500Positive News
OCS
Oculis
1.9666 of 5 stars
$18.16
+0.6%
$35.33
+94.6%
+54.9%$792.90MN/A-6.882
ANAB
AnaptysBio
1.7273 of 5 stars
$26.95
+2.9%
$42.38
+57.2%
-22.6%$791.79M$91.28M-5.56100
BGM
BGM Group
N/A$8.08
-13.2%
N/AN/A$785.54M$25.10M0.00298
CRMD
CorMedix
2.5711 of 5 stars
$11.36
+1.2%
$17.14
+50.9%
+128.2%$770.49M$82.55M51.6430
VIR
Vir Biotechnology
3.5865 of 5 stars
$5.50
-2.7%
$30.25
+450.0%
-46.5%$760.32M$74.21M-1.30580News Coverage
KALV
KalVista Pharmaceuticals
4.0739 of 5 stars
$15.22
+4.8%
$26.29
+72.7%
+6.9%$760.24MN/A-4.12100Analyst Revision
High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.4134 of 5 stars
$8.41
+9.5%
$11.75
+39.7%
+290.6%$749.68M-$1.27M-2.70200High Trading Volume

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners